Table 4. Univariable Cox regression analysis for recurrence-free survival.
| Era 1 | Era 2 | |||
|---|---|---|---|---|
| HRa (95% CIb) | p-value | HRa (95% CIb) | p-value | |
| Age at first visit (months) | 1.01 (1.00–1.01) | 0.01 | 0.99 (0.98–1.01) | 0.489 |
| Age at last treatment (months) | 1.01 (1.00–1.01) | 0.001 | 1.00 (0.98–1.01) | 0.522 |
| Weight (kg) at first OAC | 1.00 (0.98–1.03) | 0.678 | 0.99 (0.94–1.05) | 0.802 |
| Gender | 0.345 | 0.872 | ||
| Female | 1 | 1 | ||
| Male | 1.30 (0.75–2.26) | 0.96 (0.58–1.58) | ||
| Family history | 0.083 | 0.186 | ||
| No | 1 | 1 | ||
| Yes | 1.87 (0.92–3.79) | 0.54 (0.22–1.34) | ||
| Laterality | 0.164 | 0.647 | ||
| Bilateral | 1 | 1 | ||
| Unilateral | 0.63 (0.33–1.21) | 1.12 (0.68–1.86) | ||
| Side | 0.955 | 0.835 | ||
| Left | 1 | 1 | ||
| Right | 0.98 (0.57–1.71) | 1.05 (0.64–1.74) | ||
| REc class | 0.869 | 0.758 | ||
| 1 to 4 | 1 | 1 | ||
| 5 | 1.06 (0.53–2.14) | 1.11 (0.58–2.10) | ||
| ICRBd class | 0.96 | 0.399 | ||
| A/B/C | 1 | 1 | ||
| D | 0.91 (0.45–1.85) | 1.64 (0.80–3.38) | ||
| E | 0.89 (0.38–2.10) | 1.44 (0.60–3.44) | ||
| Vitreous seeds at first visit | 0.031 | 0.269 | ||
| No | 1 | 1 | ||
| Yes | 2.06 (1.07–3.97) | 0.75 (0.45–1.25) | ||
| Subretinal seeds at first visit | 0.492 | 0.598 | ||
| No | 1 | 1 | ||
| Yes | 1.40 (0.53–3.69) | 1.23 (0.57–2.64) | ||
| Germline mutation | 0.834 | 0.891 | ||
| Negative | 1 | 1 | ||
| Positive | 1.08 (0.54–2.13) | 1.04 (0.58–1.87) | ||
| Treatment naive | 0.91 | 0.673 | ||
| No | 1 | 1 | ||
| Yes | 1.03 (0.58–1.84) | 1.12 (0.66–1.88) | ||
| Intraoperative pressure hypertensive | 0.058 | 0.281 | ||
| No | 1 | 1 | ||
| Yes | 2.17 (0.97–4.85) | 1.33 (0.79–2.23) | ||
| Maximum melphalan dose | 1.14 (0.97–1.34) | 0.115 | 0.99 (0.94–1.05) | 0.783 |
| Maximum topotecan dose | 1.61 (0.96–2.69) | 0.07 | 0.99 (0.93–1.05) | 0.687 |
| Maximum carboplatin dose | 1.01 (1.00–1.02) | 0.07 | 0.99 (0.98–1.01) | 0.325 |
| Cumulative melphalan dose | 1.05 (1.01–1.08) | 0.006 | 0.99 (0.95–1.03) | 0.615 |
| Cumulative topotecan dose | 1.16 (0.99–1.37) | 0.073 | 1.00 (0.95–1.05) | 0.917 |
| Cumulative carboplatin dose | 1.00 (1.00–1.01) | 0.102 | 1.00 (0.99–1.00) | 0.442 |
| OACe interval (weeks) | 1.03 (1.00–1.05) | 0.025 | 1.03 (1.01–1.05) | 0.01 |
| OACe interval categories | 0.001 | 0.096 | ||
| >37 weeks | 1 | 1 | ||
| >24 to < = 37 weeks | 0.32 (0.16–0.64) | 0.51 (0.28–0.94) | ||
| < = 24 weeks | 0.18 (0.05–0.65) | 0.60 (0.14–2.65) | ||
| Greater than 3 infusions | 0.311 | 0.895 | ||
| No | 1 | 1 | ||
| Yes | 1.51 (0.68–3.34) | 0.96 (0.50–1.82) | ||
| Greater 50% OAe | < .001 | < .001 | ||
| No | 1 | 1 | ||
| Yes | 0.33 (0.18–0.59) | 0.37 (0.22–0.60) | ||
| First treatment OAe | 0.057 | < .001 | ||
| No | 1 | 1 | ||
| Yes | 0.44 (0.19–1.03) | 0.34 (0.20–0.56) | ||
| Number of drugs | 0.027 | 0.305 | ||
| 1 | 1 | 1 | ||
| 2 | 2.38 (1.10–5.13) | 4.92 (0.65–37.50) | ||
| 3 | 2.60 (1.27–5.29) | 4.32 (0.59–31.53) | ||
| Bridge | 0.014 | 0.337 | ||
| No | 1 | 1 | ||
| Yes | 2.50 (1.21–5.18) | 1.42 (0.69–2.91) | ||
| International Bridge | NA | 0.981 | ||
| No | 1 | |||
| Yes | NA | 1.01 (0.56–1.80) | ||
aHR = hazard ratio
bCI = confidence interval
cRE = Reese-Ellsworth
dICRB = International Classification of Retinoblastoma
eOAC = ophthalmic artery chemosurgery/ OA = ophthalmic artery